- Recombinant Proteins
- Accession Number
Proteins prepared by recombinant DNA technology.
Drug Drug Description Denileukin diftitox A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Rasburicase A recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Onercept Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. Pegsunercept Investigated for use/treatment in rheumatoid arthritis. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Elosulfase alfa A lysosomal glycosaminoglycan (GAG)-specific enzyme indicated as an enzyme replacement therapy for Mucopolysaccharidosis type IV A. Corifollitropin alfa A FSH analogue indicated for Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Turoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Dulanermin Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. Moroctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Antihemophilic factor (recombinant), PEGylated For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... Elapegademase A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. Turoctocog alfa pegol Turoctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of... Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B. Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Luspatercept An erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions. Albutrepenonacog alfa A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. Tagraxofusp A CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm. Pegilodecakin Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer). Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Rurioctocog alfa pegol Not Annotated
- Drugs & Drug Targets